Clinical trial NCT00878722: Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Official title: A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukemia
PXD101
Belinostat
Idarubicin
Lead sponsor: Valerio Therapeutics
Sponsor class: INDUSTRY
First posted: 2009-04-09
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not suitable for standard intensive therapy.

Detailed description: This trial is an open-label, multi-centre, dose-escalation Phase I/II study to evaluate safety, explore efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with idarubicin administered in two different schedules in patients with AML. The PXD101 plus idarubicin treatment will be repeated at suitable intervals (target is every 3 weeks for schedule A and every 2 weeks for schedule B) depending upon toxicities or disease progression. Safety and efficacy assessments will be performed at every cycle.

Schedule A uses PXD101 by 30 min infusion daily for 5 days every 3 weeks with escalating doses of idarubicin.

Schedule B uses escalating doses of continuous infusion (48h) of PXD101 alone or in combination with idarubicin.

In both regimens the trial may be expanded at the Maximum Tolerated Dose (MTD).

Eligibility criteria: Inclusion Criteria: (abbreviated)

1. Signed consent
2. AML patients:

   1. above 60 years in first relapse or refractory.
   2. 18-60 years 2nd relapse or refractory to at least two intensive chemotherapy regimens.
   3. above 60 years with high risk features (cytogenetics, secondary or treatment related AML) d) above 60 years with myelodysplastic syndrome with \>10% blasts in bone marrow (WHO RAEB-2 (Refractory anemia with excess blasts-2)). For patients below 60 years potential curative treatments should have been exhausted.
3. Performance status (ECOG) ≤ 2
4. Age ≥ 18 years
5. Acceptable liver, renal and bone marrow function as defined
6. Serum potassium within normal range.
7. Acceptable coagulation status as defined
8. Precautions for female patients with reproductive potential as defined

Exclusion Criteria:

1. Treatment with investigational agents within the last 4 weeks
2. Prior treatment with HDAC (Histone deacetylases) inhibitors including valproic acid
3. Prior anti-leukemic therapy (except hydroxyurea) within the last 3 weeks of trial dosing
4. Co-existing active infection (including HIV) or any co-existing medical condition likely to interfere with trial procedures, including significant cardiovascular disease
5. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures.
6. Concurrent second malignancy.
7. History of hypersensitivity to idarubicin
8. Cumulative idarubicin dose exceeding 100 mg/m², or a (with respect cardiotoxicity) corresponding dose of other anthracyclines
9. LVEF (left ventricular ejection fraction) below normal range (\< 45% )
10. Known Central Nervous System (CNS) leukemia

Primary outcomes:
measure: Maximum Tolerated Dose, Dose Limiting Toxicity
timeFrame: First Cycle
measure: Overall Response
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
Secondary outcomes:
measure: Time to Response (CR and PR)
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Duration of Response (CR and PR)
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Overall Survival
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Relapse-Free Survival
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Event-Free Survival
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Remission Duration
timeFrame: Throughout study, after each cycle for the first two cycles, then after every second cycle
measure: Belinostat Cmax
timeFrame: Samples taken in Cycle 1 only, prior to initial dose on days 4 and 5 and at end of infusion, 5, 15, and 30 min, and 1, 2, 3, 4, and 6 hours post infusion
measure: Belinostat AUC (Area Under Curve)
timeFrame: Cycle 1, prior to initial dose on days 4 and 5 and at end of infusion, 5, 15, and 30 min, and 1, 2, 3, 4, and 6 hours post infusion
measure: Elimination t½
timeFrame: Cycle 1, Samples taken in Cycle 1 only, prior to initial dose on days 4 and 5 and at end of infusion, 5, 15, and 30 min, and 1, 2, 3, 4, and 6 hours post infusion
Other outcomes:
Locations:
city: Montpellier
country: France
facility: CHU Lapeyronie
city: Paris
country: France
facility: Hôpital St. Louis
city: Homburg
country: Germany
facility: Uniklinik Homburg
city: Marburg
country: Germany
facility: Uni Hospital Marburg
city: Ulm
country: Germany
facility: Universitätsklinikum Ulm
city: Manchester
country: United Kingdom
facility: Christie Hospital NHS Trust
Study officials:
affiliation: Valerio Therapeutics
name: e-mail contact via enquiries@topotarget.com
role: STUDY_CHAIR
References: